Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.55 |
| ▸ | SMOX | Q9NWM0 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17742134 | 0.90 | MAOA (0.55) | MAOASMOXKDM1ARCOR1GAA | |
| SCHEMBL17741698 | 0.83 | MAOA (0.46) | MAOASMOXKDM1ARCOR1LCK | |
| SCHEMBL17741703 | 0.82 | MAOA (0.57) | MAOASMOXKDM1ARCOR1 | |
| SCHEMBL17731498 | 0.79 | MEN1 (0.55) | MAOASMOX | |
| SCHEMBL17742131 | 0.77 | ADORA2A (0.58) | MAOASMOXKDM1ARCOR1HSD17B10 | |
| SCHEMBL17741878 | 0.76 | MAOA (0.64) | MAOASMOXKDM1ARCOR1GAA | |
| SCHEMBL17742090 | 0.75 | MAOA (0.56) | MAOASMOXKDM1ARCOR1 | |
| SCHEMBL17742133 | 0.74 | MAOA (0.57) | MAOASMOXKDM1ARCOR1GAA | |
| SCHEMBL13407800 | 0.71 | KDM1A (0.52) | MAOAKDM1ACHRM4MAOBGAA | |
| SCHEMBL17742091 | 0.71 | MAOA (0.47) | MAOASMOXGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2019-03-26 | — | — | US | disclosed |
| WO-2016073424-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3A | MAOA 311/4885SMOX 1960/4885KDM1A 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.